You are here

Atorvastatin For The Reduction Of Ventricular Arrhythmias

Last updated on October 4, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Aalst, , Belgium
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arrhythmia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Eligible subjects were male or female subjects, age >18 years, with clinically
documented coronary artery disease and life-threatening ventricular arrhythmias who
met the following criteria:

- Were scheduled for an ICD implantation or had an ICD implantation within 1 month,
according to the class I American College of Cardiology/American Heart Association
(ACC/AHA) practice guidelines for ICD therapy

OR

- Were already treated with an ICD for a class I ACC/AHA indication for more than one
month, provided they received at least one appropriate ICD intervention (shock or
antitachycardia pacing (ATP) for ventricular tachycardia or ventricular fibrillation)
during the preceding six months

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with ventricular arrhythmias in the acute phase of myocardial infarction
(first 48 hours).

- Patients with incessant ventricular tachycardia.

- Patients with ventricular arrhythmias without underlying coronary artery disease.

- Patients with a transient or reversible cause of ventricular arrhythmias (including
significant electrolyte disturbances or drug induced proarrhythmia).

NCT00457340
Pfizer
Completed
Atorvastatin For The Reduction Of Ventricular Arrhythmias

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Arrhythmia
NCT00137293
All Genders
18+
Years
Multiple Sites
Arrhythmia
NCT00543946
Males
20+
Years
Shinagawa-Ku, Tokyo
Arrhythmia
NCT00137332
All Genders
18+
Years
Multiple Sites
Atorvastatin For The Reduction Of Ventricular Arrhythmias
Cholesterol Lowering and Arrhythmia Recurrences After Internal Defibrillator Implantation (CLARIDI)
To assess in patients with CAD [coronary artery disease] and an implantable defibrillator the effect of atorvastatin 80 mg versus placebo on the first recurrence of a ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation requiring ICD [implantable cardioverter defibrillator] intervention) within one year after randomization.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Arrhythmia
Drug: Atorvastatin 80mg
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
220
September 2004
Not Provided

Inclusion Criteria:

  • Eligible subjects were male or female subjects, age >18 years, with clinically documented coronary artery disease and life-threatening ventricular arrhythmias who met the following criteria:
  • Were scheduled for an ICD implantation or had an ICD implantation within 1 month, according to the class I American College of Cardiology/American Heart Association (ACC/AHA) practice guidelines for ICD therapy

OR

  • Were already treated with an ICD for a class I ACC/AHA indication for more than one month, provided they received at least one appropriate ICD intervention (shock or antitachycardia pacing (ATP) for ventricular tachycardia or ventricular fibrillation) during the preceding six months

Exclusion Criteria:

  • Patients with ventricular arrhythmias in the acute phase of myocardial infarction (first 48 hours).
  • Patients with incessant ventricular tachycardia.
  • Patients with ventricular arrhythmias without underlying coronary artery disease.
  • Patients with a transient or reversible cause of ventricular arrhythmias (including significant electrolyte disturbances or drug induced proarrhythmia).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Greece
 
 
NCT00457340
A2581020
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2009

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now